Publication: Effects of immunosuppressive drugs on COVID-19 severity in patients with autoimmune hepatitis
dc.contributor.author | Efe, Cumali | |
dc.contributor.author | Lammert, Craig | |
dc.contributor.author | Taşcılar, Koray | |
dc.contributor.author | Dhanasekaran, Renumathy | |
dc.contributor.author | Ebik, Berat | |
dc.contributor.author | Higuera-de la Tijera, Fatima | |
dc.contributor.author | Çalışkan, Ali R. | |
dc.contributor.author | Peralta, Mirta | |
dc.contributor.author | Gerussi, Alessio | |
dc.contributor.author | Massoumi, Hatef | |
dc.contributor.author | Catana, Andreea M. | |
dc.contributor.author | Purnak, Tuğrul | |
dc.contributor.author | Rigamonti, Cristina | |
dc.contributor.author | Aldana, Andres J. G. | |
dc.contributor.author | Khakoo, Nidah | |
dc.contributor.author | Nazal, Leyla | |
dc.contributor.author | Frager, Shalom | |
dc.contributor.author | Demir, Nurhan | |
dc.contributor.author | Irak, Kader | |
dc.contributor.author | Melekoğlu-Ellik, Zeynep | |
dc.contributor.author | Kaçmaz, Hüseyin | |
dc.contributor.author | Balaban, Yasemin | |
dc.contributor.author | Atay, Kadri | |
dc.contributor.author | Eren, Fatih | |
dc.contributor.author | Alvares-da-Silva, Mario R. | |
dc.contributor.author | Cristoferi, Laura | |
dc.contributor.author | Urzua, Alvaro | |
dc.contributor.author | Eskazan, Tuğçe | |
dc.contributor.author | Magro, Bianca | |
dc.contributor.author | Snijders, Romee | |
dc.contributor.author | Barutcu, Sezgin | |
dc.contributor.author | Lytvyak, Ellina | |
dc.contributor.author | Zazueta, Godolfino M. | |
dc.contributor.author | Demirezer-Bolat, Aylin | |
dc.contributor.author | Aydın, Mesut | |
dc.contributor.author | Heurgue-Berlot, Alexandra | |
dc.contributor.author | De Martin, Eleonora | |
dc.contributor.author | Ekin, Nazım | |
dc.contributor.author | Yıldırım, Sümeyra | |
dc.contributor.author | Yavuz, Ahmet | |
dc.contributor.author | Bıyık, Murat | |
dc.contributor.author | Narro, Graciela C. | |
dc.contributor.author | Kıyıcı, Murat | |
dc.contributor.author | Akyıldız, Murat | |
dc.contributor.author | Kahramanoğlu-Aksoy, Evrim | |
dc.contributor.author | Vincent, Maria | |
dc.contributor.author | Carr, Rotonya M. | |
dc.contributor.author | Günşar, Fulya | |
dc.contributor.author | Reyes, Eira C. | |
dc.contributor.author | Harputluoğlu, Murat | |
dc.contributor.author | Aloman, Costica | |
dc.contributor.author | Gatselis, Nikolaos K. | |
dc.contributor.author | Ustundağ, Yücel | |
dc.contributor.author | Brahm, Javier | |
dc.contributor.author | Vargas, Nataly C. E. | |
dc.contributor.author | Güzelbulut, Fatih | |
dc.contributor.author | Garcia, Sandro R. | |
dc.contributor.author | Aguirre, Jonathan | |
dc.contributor.author | Anders, Margarita | |
dc.contributor.author | Ratusnu, Natalia | |
dc.contributor.author | Hatemi, İbrahim | |
dc.contributor.author | Mendizabal, Manuel | |
dc.contributor.author | Floreani, Annarosa | |
dc.contributor.author | Fagiuoli, Stefano | |
dc.contributor.author | Silva, Marcelo | |
dc.contributor.author | Idılman, Ramazan | |
dc.contributor.author | Satapathy, Sanjaya K. | |
dc.contributor.author | Silveira, Marina | |
dc.contributor.author | Drenth, Joost P. H. | |
dc.contributor.author | Dalekos, George N. | |
dc.contributor.author | Assis, David N. | |
dc.contributor.author | Bjornsson, Einar | |
dc.contributor.author | Boyer, James L. | |
dc.contributor.author | Yoshida, Eric M. | |
dc.contributor.author | Invernizzi, Pietro | |
dc.contributor.author | Levy, Cynthia | |
dc.contributor.author | Montano-Loza, Aldo J. | |
dc.contributor.author | Schiano, Thomas D. | |
dc.contributor.author | Ridruejo, Ezequiel | |
dc.contributor.author | Wahlin, Staffan | |
dc.contributor.buuauthor | KIYICI, MURAT | |
dc.contributor.department | Bursa Uludağ Üniversitesi/Tıp Fakültesi/Gastroenteroloji Anabilim Dalı. | |
dc.contributor.researcherid | FHW-0015-2022 | |
dc.date.accessioned | 2024-06-14T07:15:31Z | |
dc.date.available | 2024-06-14T07:15:31Z | |
dc.date.issued | 2021-11-28 | |
dc.description.abstract | Background We investigated associations between baseline use of immunosuppressive drugs and severity of Coronavirus Disease 2019 (COVID-19) in autoimmune hepatitis (AIH). Patients and methods Data of AIH patients with laboratory confirmed COVID-19 were retrospectively collected from 15 countries. The outcomes of AIH patients who were on immunosuppression at the time of COVID-19 were compared to patients who were not on AIH medication. The clinical courses of COVID-19 were classified as (i)-no hospitalization, (ii)-hospitalization without oxygen supplementation, (iii)-hospitalization with oxygen supplementation by nasal cannula or mask, (iv)-intensive care unit (ICU) admission with non-invasive mechanical ventilation, (v)-ICU admission with invasive mechanical ventilation or (vi)-death and analysed using ordinal logistic regression. Results We included 254 AIH patients (79.5%, female) with a median age of 50 (range, 17-85) years. At the onset of COVID-19, 234 patients (92.1%) were on treatment with glucocorticoids (n = 156), thiopurines (n = 151), mycophenolate mofetil (n = 22) or tacrolimus (n = 16), alone or in combinations. Overall, 94 (37%) patients were hospitalized and 18 (7.1%) patients died. Use of systemic glucocorticoids (adjusted odds ratio [aOR] 4.73, 95% CI 1.12-25.89) and thiopurines (aOR 4.78, 95% CI 1.33-23.50) for AIH was associated with worse COVID-19 severity, after adjusting for age-sex, comorbidities and presence of cirrhosis. Baseline treatment with mycophenolate mofetil (aOR 3.56, 95% CI 0.76-20.56) and tacrolimus (aOR 4.09, 95% CI 0.69-27.00) were also associated with more severe COVID-19 courses in a smaller subset of treated patients. Conclusion Baseline treatment with systemic glucocorticoids or thiopurines prior to the onset of COVID-19 was significantly associated with COVID-19 severity in patients with AIH. | |
dc.description.sponsorship | Ministry of Education, Universities and Research (MIUR) | |
dc.identifier.doi | 10.1111/liv.15121 | |
dc.identifier.eissn | 1478-3231 | |
dc.identifier.endpage | 614 | |
dc.identifier.issn | 1478-3223 | |
dc.identifier.issue | 3 | |
dc.identifier.startpage | 607 | |
dc.identifier.uri | https://doi.org/10.1111/liv.15121 | |
dc.identifier.uri | https://onlinelibrary.wiley.com/doi/10.1111/liv.15121 | |
dc.identifier.uri | https://hdl.handle.net/11452/42192 | |
dc.identifier.volume | 42 | |
dc.identifier.wos | 000729531700001 | |
dc.indexed.wos | WOS.SCI | |
dc.language.iso | en | |
dc.publisher | Wiley | |
dc.relation.journal | Liver International | |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi | |
dc.rights | info:eu-repo/semantics/openAccess | |
dc.subject | Liver-transplant recipients | |
dc.subject | Sars-CoV-2 infection | |
dc.subject | Autoimmunity | |
dc.subject | Azathioprine | |
dc.subject | Budesonide | |
dc.subject | Liver transplantation | |
dc.subject | Mercaptopurine | |
dc.subject | Sars-CoV-2 | |
dc.subject | Gastroenterology & hepatology | |
dc.title | Effects of immunosuppressive drugs on COVID-19 severity in patients with autoimmune hepatitis | |
dc.type | Article | |
dspace.entity.type | Publication | |
relation.isAuthorOfPublication | b364b52b-c416-4987-b080-93f6f81ecb3e | |
relation.isAuthorOfPublication.latestForDiscovery | b364b52b-c416-4987-b080-93f6f81ecb3e |
Files
Original bundle
1 - 1 of 1